Akero Therapeutics/$AKRO

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX

About Akero Therapeutics

Akero Therapeutics Inc is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for serious metabolic diseases with high unmet medical needs. Its focus is nonalcoholic steatohepatitis (MASH), or NASH, a disease without any approved therapies. The company's product candidate efruxifermin is an FGF21 analog with properties that have the potential to address the core processes underlying NASH pathogenesis.

Ticker

$AKRO
Sector
Health Care
Primary listing
NASDAQ

Industry

Biotechnology
Headquarters
South San Francisco, United States

Employees

69

ISIN

US00973Y1082
Website
akerotx.com

AKRO Metrics

BasicAdvanced
$4.5B
-
-$3.74
-0.13
-

What the Analysts think about AKRO

Analyst ratings (Buy, Hold, Sell) for Akero Therapeutics stock.

Bulls say / Bears say

Wolfe Research initiated coverage on Akero Therapeutics with an 'Outperform' rating and a $40 price target, citing the potential of its NASH treatment, efruxifermin (EFX), and estimating peak revenues of approximately $3 billion by 2040. (investing.com)
Akero Therapeutics announced the pricing of an upsized public offering, raising approximately $350 million, which is expected to support the advancement of its clinical programs. (tradingview.com)
Analysts have set a consensus price target of $76.29 for Akero Therapeutics, indicating strong confidence in the company's future performance. (americanbankingnews.com)
Akero Therapeutics' stock plummeted 67% after its NASH treatment, efruxifermin, missed the primary endpoint in a mid-stage trial, raising concerns about its efficacy. (schaeffersresearch.com)
The company's CFO sold shares worth over $4.3 million, which could be perceived as a lack of confidence in the company's near-term prospects. (investing.com)
ALKEON CAPITAL MANAGEMENT LLC reduced its stake in Akero Therapeutics, possibly indicating diminished confidence from institutional investors. (gurufocus.com)
Data summarised monthly by Lightyear AI. Last updated on 4 Jun 2025.

AKRO Financial Performance

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

AKRO Earnings Performance

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-

AKRO News

AllArticlesVideos
Bronstein, Gewirtz & Grossman, LLC Encourages Akero Therapeutics, Inc. (AKRO) Shareholders to Inquire about Securities Investigation

Bronstein, Gewirtz & Grossman, LLC Encourages Akero Therapeutics, Inc. (AKRO) Shareholders to Inquire about Securities Investigation

Accesswire·3 weeks ago
Bronstein, Gewirtz & Grossman, LLC Is Investigating Akero Therapeutics, Inc. (AKRO) And Encourages Shareholders to Connect

Bronstein, Gewirtz & Grossman, LLC Is Investigating Akero Therapeutics, Inc. (AKRO) And Encourages Shareholders to Connect

Accesswire·4 weeks ago
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Akero Therapeutics, Inc. (AKRO) And Encourages Shareholders to Reach Out

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Akero Therapeutics, Inc. (AKRO) And Encourages Shareholders to Reach Out

Accesswire·4 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $AKRO

Sign up or log in to buy
Capital at risk
Market closed

Upcoming events

No upcoming events
FAQs